AbbVie's Rheumatoid Arthritis Drug Succeeds in Late-stage Trial AbbVie's Rheumatoid Arthritis Drug Succeeds in Late-stage Trial
U.S. drugmaker AbbVie Inc said on Wednesday late-stage data showed its rheumatoid arthritis drug performed better than a placebo in reducing symptoms in moderate-to-severe patients who have not adequately responded to standard treatments.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - June 8, 2017 Category: Surgery Tags: Rheumatology News Source Type: news

New drug could fight rheumatoid arthritis symptoms - ‘exciting’ results for patients
RHEUMATOID arthritis patients are a step closer to a new, effective treatment following a breakthrough study. Symptoms of rheumatoid arthritis can be painful but experts have hailed the results as 'exciting'. (Source: Daily Express - Health)
Source: Daily Express - Health - June 8, 2017 Category: Consumer Health News Source Type: news

Will Rheumatoid Arthritis Nodules Go Away?
Title: Will Rheumatoid Arthritis Nodules Go Away?Category: Doctor's& Expert's views on SymptomsCreated: 6/8/2017 12:00:00 AMLast Editorial Review: 6/8/2017 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - June 8, 2017 Category: Rheumatology Source Type: news

What's the Rheumatoid Arthritis Prognosis?
Title: What's the Rheumatoid Arthritis Prognosis?Category: Doctor's& Expert's views on SymptomsCreated: 6/8/2017 12:00:00 AMLast Editorial Review: 6/8/2017 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - June 8, 2017 Category: Rheumatology Source Type: news

AbbVie's rheumatoid arthritis drug succeeds in trial
(Reuters) - AbbVie Inc said on Wednesday its oral rheumatoid arthritis drug succeeded in a late-stage study on patients who had not adequately responded to standard treatments. (Source: Reuters: Health)
Source: Reuters: Health - June 7, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie's rheumatoid arthritis drug succeeds in late-stage trial
(Reuters) - U.S. drugmaker AbbVie Inc said on Wednesday its drug to treat moderate-to-severe rheumatoid arthritis met the main goal in a late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - June 7, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Arthritis symptoms - painful joints could be a sign of THIS life-threatening condition
ARTHRITIS - either osteoarthritis or rheumatoid arthritis - causes pain the in joints, including the hips, wrists, ankles and knees. (Source: Daily Express - Health)
Source: Daily Express - Health - June 7, 2017 Category: Consumer Health News Source Type: news

What Are Home Remedies for Rheumatoid Arthritis?
Title: What Are Home Remedies for Rheumatoid Arthritis?Category: Doctor's& Expert's views on SymptomsCreated: 6/7/2017 12:00:00 AMLast Editorial Review: 6/7/2017 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - June 7, 2017 Category: Rheumatology Source Type: news

Putting Disability Benefits on the Election agenda
Volunteers, campaigners and staff from Arthritis Research UK attended the National Disability Hustings this week hosted by a consortium of charities working to support people with disabilities.Over 150 disabled people gathered in Church House to hear from, and question, representatives from the political parties. The panel was made up of Penny Mordaunt, most recent Minister for Disabled People representing the Conservatives, Kate Green, former Shadow Minister for Disabled People for Labour, and Baroness Brinton, a Liberal Democrat Peer and former health spokesperson. Baroness Brinton was also the first wheelchair user to h...
Source: Arthritis Research UK - June 6, 2017 Category: Rheumatology Source Type: news

Risk Factors of Cervical Spine Instabilities in RA Risk Factors of Cervical Spine Instabilities in RA
A study explores the prognostic factors that may identify the risk of cervical spine instabilities among patients with rheumatoid arthritis.Spine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2017 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Kevzara (sarilumab) for the Treatment of Rheumatoid Arthritis
Kevzara ® (sarilumab) is a human monoclonal antibody indicated for the treatment of adult patients with moderate to severely active rheumatoid arthritis (RA). (Source: Drug Development Technology)
Source: Drug Development Technology - June 4, 2017 Category: Pharmaceuticals Source Type: news

9 Reasons To Drink Water That Have Nothing To Do With Being Thirsty
Exactly how much water people need to drink each day to stay hydrated is a subject of debate. You’ve likely heard that you need at least six to eight glasses a day, but the real figure depends on other factors. How much activity you get, the climate you live in and how much water you get from sources like fruits and vegetables all matters. The good news is that as long as you make water your main beverage, drink when you’re thirsty and consume it with meals, you don’t need to get caught up tallying glasses, according to the U.S. Centers for Disease Control and Prevention. But keeping properly hydrate...
Source: Healthy Living - The Huffington Post - June 2, 2017 Category: Consumer Health News Source Type: news

Poor Prognostic Factors Guiding Treatment Decisions in RA Poor Prognostic Factors Guiding Treatment Decisions in RA
Prognostic factors are used to guide treatment strategies for rheumatoid arthritis -- but how are these factors currently defined?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 1, 2017 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

In Rheumatoid Arthritis, Adding a Biologic Agent Before Trying Triple Therapy Likely Not Cost-Effective (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH For patients with active rheumatoid arthritis despite methotrexate therapy, adding a biologic agent (e.g., etanercept) before trying triple therapy would lead to substantial cost increases without much … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 30, 2017 Category: Primary Care Source Type: news

Falls and their association with physical tests, functional capacity, clinical and demographic factors in patients with rheumatoid arthritis - Louren ço MA, Roma I, Assis MR.
OBJECTIVE: To evaluate the occurrence of falls reported by rheumatoid arthritis patients and its relation to disease activity, functional capacity and physical fitness. MATERIALS AND METHODS: A cross-sectional study constituted by a sample of 97 rh... (Source: SafetyLit)
Source: SafetyLit - May 29, 2017 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Biologics before triple therapy not cost effective for rheumatoid arthritis
(American College of Physicians) Stepping up to biologic therapy when methotrexate monotherapy fails offers minimal incremental benefit over using a combination of drugs known as triple therapy, yet incurs large costs for treating rheumatoid arthritis (RA). Results of a comprehensive cost-effectiveness analysis suggest that patients who have RA and no contraindications to triple therapy should use it prior to a biologic as the next regimen. The study is published in Annals of Internal Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 29, 2017 Category: International Medicine & Public Health Source Type: news

FDA approves Sanofi and Regeneron ’s Kevzara for adult rheumatoid arthritis
Sanofi and Regeneron Pharmaceuticals ’ drug Kevzara (sarilumab) has received the US Food and Drug Administration (FDA) approval to treat adult patients affected with moderately to severely active rheumatoid arthritis (RA). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 23, 2017 Category: Pharmaceuticals Source Type: news

UK watchdog accuses Merck of restricting biosimilar competition
Britain’s Competition and Markets Authority accused Merck‘s (NYSE:MRK) European unit, Merck Sharp & Dohme, of conducting an unfair discount scheme that it said was designed to restrict competition from biosimilar copies of the company’s drug, Remicade. Remicade is an antibody drug used to treat rheumatoid arthritis, ulcerative colitis and Chron’s disease. It was the 1st antibody drug to face competition from copycat versions in the European markets. Biosimilar drugmakers, including South Korea’s Celltrion, have launched discounted products that are “similar” enough to Remicade ...
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Wall Street Beat Merck Source Type: news

FDA Approves Sarilumab for Adults With Rheumatoid Arthritis FDA Approves Sarilumab for Adults With Rheumatoid Arthritis
The drug will be marketed in self-injectible prefilled syringes and pens to be used once every 2 weeks. It offers an alternative to drugs such as methotrexate.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 23, 2017 Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news

FDA Gives Nod to Sarilumab for Rheumatoid Arthritis
(MedPage Today) -- Can be used as monotherapy or with methotrexate for active RA (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 23, 2017 Category: American Health Source Type: news

Medical abbreviations: A language WNL
Patient A+0x3, ST with PVCs and PACs.  Lungs clear bilaterally with POX 98% on RA and SOB on exertion,  PPP, NPO after midnight. PERRLA. Normal BSx4 quadrants. Abd dressing C/D/I C scant amt of serosang drainage. MAE, SBA, and OOB as tolerated. BP WNL. NS infusing @75 ml/hr through RTL PICC, F/P. Reading medical charts can be confusing to those not familiar with medical terminology and abbreviations.  The paragraph above can be frustrating for a new monitor who already had to learn research terminology but now they have to develop their medical terminology skillset.  Let’s take a look at a few com...
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Blog IMARC Source Type: news

Sanofi and Regeneron announce FDA Approval of Kevzara ® (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients
Sanofi and Regeneron Pharmaceuticals, Inc. have announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX). (Source: World Pharma News)
Source: World Pharma News - May 23, 2017 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

​Sanofi Genzyme takes on world’s top-selling drugs with new approval
With Monday ’s announcement that U.S. regulators have approved a drug for rheumatoid arthritis developed by Sanofi Genzyme and Regeneron Pharmaceuticals, the two drugmakers revealed a tried-and-true strategy to take on the world’s number one and number three best-selling drugs, which also happen to be for t hat same disease: give it a lower price. Cambridge-based Sanofi Genzyme (NYSE: SNY) and Tarrytown, N.Y.-based Regeneron (NYSE: REGN) will market their new drug, which has the generic name of… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 23, 2017 Category: Health Management Authors: Don Seiffert Source Type: news

​Sanofi Genzyme takes on world’s top-selling drugs with new approval
With Monday ’s announcement that U.S. regulators have approved a drug for rheumatoid arthritis developed by Sanofi Genzyme and Regeneron Pharmaceuticals, the two drugmakers revealed a tried-and-true strategy to take on the world’s number one and number three best-selling drugs, which also happen to be for t hat same disease: give it a lower price. Cambridge-based Sanofi Genzyme (NYSE: SNY) and Tarrytown, N.Y.-based Regeneron (NYSE: REGN) will market their new drug, which has the generic name of… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 23, 2017 Category: Biotechnology Authors: Don Seiffert Source Type: news

Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval
(Reuters) - The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals and Sanofi's biotech drug for adults with moderate to severe rheumatoid arthritis, the two companies said on Monday. (Source: Reuters: Health)
Source: Reuters: Health - May 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Sanofi and Regeneron Announce FDA Approval of Kevzara (sarilumab) for Rheumatoid Arthritis
PARIS and TARRYTOWN, N.Y., May 22, 2017 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) approval of Kevzara (sarilumab) for the treatment of adult patients with moderately to... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 22, 2017 Category: Drugs & Pharmacology Source Type: news

Janssen Biotech goes to court to block launch of Remicade biosimilar
Jansen Biotech is not going to let a second biosimilar version of its blockbuster rheumatoid arthritis drug Remicade hit pharmacy shelves in the United States without a fight. The Horsham, Pa.-based subsidiary of Johnson& Johnson (NYSE: JNJ) has filed a patent infringement lawsuit with U.S. District Court in New Jersey to prevent Samsung Bioepis Co. Ltd. of South Korea from introducing Renflexis later this year. Biosimilar products are different from generic drugs, which are chemically identical… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - May 19, 2017 Category: American Health Authors: John George Source Type: news

Janssen files suit in U.S. to block sale of Samsung Bioepis' Remicade copy
SEOUL (Reuters) - A unit of healthcare conglomerate Johnson& Johnson filed a lawsuit to block a copy of its rheumatoid arthritis drug Remicade made by South Korea's Samsung Bioepis Co Ltd from being sold in the United States. (Source: Reuters: Health)
Source: Reuters: Health - May 19, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Vegetarian diet could cut obesity risk
Strongest vegetarian diet results in 43% smaller risk of obesity Related items fromOnMedica Mediterranean diet reduces brain shrinkage in elderly Sponsorship and ad bans needed to tackle child obesity Gluten-free diet not recommended for people without coeliac disease Study casts doubts on alternate-day fasting diet Obesity may skew results of rheumatoid arthritis blood tests in women (Source: OnMedica Latest News)
Source: OnMedica Latest News - May 19, 2017 Category: UK Health Source Type: news

Four-week Methotrexate Break Improves Flu Shot Response in RA Patients Four-week Methotrexate Break Improves Flu Shot Response in RA Patients
Temporarily withholding methotrexate (MTX) can improve the efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis (RA), according to a new randomized clinical trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 18, 2017 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

A Treat-to-Target Strategy Preserves Work Capacity in RA A Treat-to-Target Strategy Preserves Work Capacity in RA
Find out how a treat-to-target strategy using combination conventional DMARD therapy may help improve work outcomes among rheumatoid arthritis patients.Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 18, 2017 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Trial demonstrates benefits of learning sessions for managing rheumatoid arthritis
(Wiley) A new study found that group-based quality improvement sessions help rheumatologists care for rheumatoid arthritis patients with the recommended 'treat to target' (TTT) approach to care. This approach involves setting a target for treatment, measuring progress towards achieving the target regularly, altering treatments until reaching and maintaining target, and sharing the decisions with patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 17, 2017 Category: International Medicine & Public Health Source Type: news

Rheumatoid arthritis: Does pregnancy affect symptoms?
(Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - May 17, 2017 Category: Consumer Health News Source Type: news

Management Considerations in Cancer Patients With Rheumatoid Arthritis
Patients with cancer and concomitant rheumatoid arthritis pose special challenges. Many therapies for rheumatoid arthritis can increase the risk of adverse events during cancer therapy because they are immunosuppressive. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2017 Category: Cancer & Oncology Authors: Kristina Goutsouliak, MD Maria E. Suarez-Almazor, MD, PhD Richard J. Zogala, MD Tags: Oncology Journal Source Type: news

Nurses Have A Message For Congress: We Won't Accept 'Lord Of The Flies' Health Care
As scores of red-clad registered nurses stride through the halls of Congressional office buildings this week, they’ll have some other people on their minds. The postal worker who told us his wife was diagnosed with breast cancer and whose disability coverage expired after six months and had to cover thousands of dollars more out of pocket for her treatment. The 57-year-old California contractor who now pays $22,000 a year for health insurance for himself and his wife. “I’m OK with paying high insurance premiums if it helps provide health care for others, but I am mad as hell at the prospect of paying even...
Source: Healthy Living - The Huffington Post - May 9, 2017 Category: Consumer Health News Source Type: news

Welby launches three more apps for pharmas J & J, UCB, and Nippon Shinyaku
Japanese health app maker Welby announced three new apps last month developed in partnership with pharma companies. Welby will add to its lineup three apps available only in Japan: an app for irritable bowel disease patients with Johnson& Johnson subsidiary Janssen; an app for pulmonary arterial hypertension (PAH) patients with Japanese pharma company  Nippon Shinyaku, and an app for rheumatoid arthritis patients with UCB Japan. (Source: mobihealthnews)
Source: mobihealthnews - May 8, 2017 Category: Information Technology Source Type: news

Common rheumatoid arthritis risk factors 'also affect those of African descent'
Genetic and environmental factors associated with rheumatoidarthritis in people from European and Asian backgrounds also apply to people of African ancestry. This is according to a new Arthritis Research UK-funded study led by King's College London, which offers evidence of a shared genetic and environmental underpinning for the disease that is consistent across European, Asian and African ancestry populations. Assessing risk factors among a black British population The study, published in the medical journal Rheumatology, looked at data from 197 people withrheumatoid arthritis and 868 controls in south London, all of ...
Source: Arthritis Research UK - May 4, 2017 Category: Rheumatology Source Type: news

Heart attack - if YOU suffer with symptoms of THIS condition you could be at risk
RHEUMATOID arthritis sufferers are more at risk of developing a condition called atherosclerosis, a chronic inflammatory condition affecting the heart which can increase the likelihood of having a deadly heart attack. (Source: Daily Express - Health)
Source: Daily Express - Health - May 3, 2017 Category: Consumer Health News Source Type: news

Rheumatoid arthritis sufferers could be at greater risk of THIS silent killer
RHEUMATOID arthritis sufferers are more at risk of developing a condition called atherosclerosis, a chronic inflammatory condition affecting the heart. (Source: Daily Express - Health)
Source: Daily Express - Health - May 3, 2017 Category: Consumer Health News Source Type: news

Regeneron and Sanofi Announce Kevzara(R) (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA
New action date for Kevzara U.S. BLA is May 22, 2017 TARRYTOWN, N.Y. and PARIS, April 28, 2017 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administra... Biopharmaceuticals Regeneron Pharmaceuticals, Sanofi, Kevzara, sarilumab, rheumatoid arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 28, 2017 Category: Pharmaceuticals Source Type: news

TfL launches badge to recognise customers with invisible impairments
(Source: TfL)Transport for London (TfL) has launched a‘Please offer me a seat’ badge to recognise customers with invisible impairments.The‘Please Offer Me a Seat’ badge and card was created following requests from customers, particularly those with invisible impairments, conditions and illnesses, who struggle to get a seat as their need for one isn’t immediately obvious.A six-week trial with 1,200 users was held in autumn last year to test if the badge and card would help people getting a seat. Over the course of the trial, participants’ confidence in using the network increased. More th...
Source: Arthritis Research UK - April 27, 2017 Category: Rheumatology Source Type: news

Can-Fite to begin Phase III trial of piclidenoson in Israel to treat rheumatoid arthritis
Biotechnology company Can-Fite BioPharma has obtained approval from the Institutional Review Board (IRB) of Barzilai Medical Center in Israel, to begin patient enrolment in the Phase III ACRobat clinical trial of piclidenoson for the treatment of rhe … (Source: Drug Development Technology)
Source: Drug Development Technology - April 26, 2017 Category: Pharmaceuticals Source Type: news

Cost controls help offset lower Amgen first-quarter drug sales
(Reuters) - Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug. (Source: Reuters: Health)
Source: Reuters: Health - April 26, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Early Treatment Equals Better Results for Rheumatoid Arthritis
Title: Early Treatment Equals Better Results for Rheumatoid ArthritisCategory: Health NewsCreated: 4/25/2017 12:00:00 AMLast Editorial Review: 4/26/2017 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - April 26, 2017 Category: Rheumatology Source Type: news

Early Treatment Equals Better Results for Rheumatoid Arthritis
Study found less disability, lower risk of early deathSource: HealthDay Related MedlinePlus Pages: Autoimmune Diseases, Rheumatoid Arthritis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - April 25, 2017 Category: Consumer Health News Source Type: news

Eli Lilly ’ s diabetes drugs boost Q1 revenue, earnings
Shares in Eli Lilly (NYSE:LLY) fell slightly today as the company met expectations on Wall Street with its 1st quarter financial results. The company has faced its share of issues in the last year – Lilly took a $150 million hit in November after its Alzheimer’s drug failed in a clinical trial and this month, the FDA rejected its rheumatoid arthritis drug. But the company’s diabetes therapies, such as Trulicity and Humalog, helped to propel the company to an adjusted quarterly profit that beat expectations on The Street. “We are encouraged by another solid performance from Lilly’s ov...
Source: Mass Device - April 25, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Diabetes MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat Eli Lilly & Co. Source Type: news

Early Treatment Equals Better Results for Rheumatoid Arthritis
TUESDAY, April 25, 2017 -- Treating rheumatoid arthritis early may make for better outcomes, a new study suggests. Patients who were treated within six months of developing the first signs of the autoimmune disease did better in the long run and... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 25, 2017 Category: Journals (General) Source Type: news

Sanofi and Regeneron ’s Kevzara receives CHMP opinion to treat Rheumatoid Arthritis
Regeneron Pharmaceuticals and Sanofi ’s Kevzara (sarilumab) has received a positive opinion from the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) to treat adult patients with moderately to severely active rheu… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 24, 2017 Category: Pharmaceuticals Source Type: news

Rheumatoid arthritis patients 'at an increased risk of atherosclerosis'
This study confirms increased prevalence of atherosclerosis in rheumatoid arthritis and provides data to support the hypothesis that patients have a high-risk plaque phenotype." Arthritis Research UK's view Dr Natalie Carter, head of research liaison and evaluation at Arthritis Research UK, said:"Rheumatoid arthritis is an incredibly debilitating condition that affects more than 400,000 people within the UK. The condition can not only limit a person's ability to live their everyday life to the full, but it can also put them at higher risk of cardiovascular disease. "This study not only reinforces the...
Source: Arthritis Research UK - April 24, 2017 Category: Rheumatology Source Type: news

Early Treatment Boosts Long-term Rheumatoid Arthritis Outcomes Early Treatment Boosts Long-term Rheumatoid Arthritis Outcomes
Early treatment boosts long-term arthritis outcomes and may be contributing to lower arthritis-related mortality, two new studies suggested.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 24, 2017 Category: Consumer Health News Tags: Rheumatology News Source Type: news